News

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
The pharmaceutical firm Novo Nordisk is pursuing a multipronged strategy to regain market share that it has lost to Eli Lilly ...
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...